KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $510.3 million.

  • West Pharmaceutical Services' Cost of Revenue rose 582.75% to $510.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 378.48%. This contributed to the annual value of $1.9 billion for FY2024, which is 407.01% up from last year.
  • West Pharmaceutical Services' Cost of Revenue amounted to $510.3 million in Q3 2025, which was up 582.75% from $492.6 million recorded in Q2 2025.
  • West Pharmaceutical Services' 5-year Cost of Revenue high stood at $510.3 million for Q3 2025, and its period low was $398.8 million during Q1 2021.
  • In the last 5 years, West Pharmaceutical Services' Cost of Revenue had a median value of $453.8 million in 2023 and averaged $452.1 million.
  • Per our database at Business Quant, West Pharmaceutical Services' Cost of Revenue skyrocketed by 2300.51% in 2021 and then increased by 14.34% in 2022.
  • West Pharmaceutical Services' Cost of Revenue (Quarter) stood at $430.2 million in 2021, then grew by 3.81% to $446.6 million in 2022, then rose by 1.61% to $453.8 million in 2023, then grew by 4.72% to $475.2 million in 2024, then increased by 7.39% to $510.3 million in 2025.
  • Its Cost of Revenue was $510.3 million in Q3 2025, compared to $492.6 million in Q2 2025 and $466.1 million in Q1 2025.